Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2010
Highlights from the Q1 2010 review of medical device and in vitro diagnostics/research dealmaking: With most of the funding in the form of venture rounds, medical device financing totaled $548 million in the second quarter, a 10% drop from Q1. Device acquisitions picked up, with 18 transactions completed for an aggregate $4.4 billion. Including GenMark's IPO, the first done in the sector since November 2007, in vitro diagnostic/research financing more than doubled Q1's dollar volume, reaching $364 million in the second quarter. The four IVD/Research acquisitions done in Q2 totalled $226 million.
In this issue, we present another installment of our quarterly
review of medical device, in vitro diagnostics, and
research/analytical dealmaking – for the second quarter of
2010. Our data come from Elsevier's Strategic
Transactions.
Amanda Micklus and Maureen Riordan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
